Skip to main content
Log in

Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Five healthy male volunteers received canrenoate-K 200 mg (Sincomen® pro injectione) by intravenous injection and one week later spironolactone 200 mg (Sincomen®-100) orally. Plasma levels and urinary excretion of unchanged canrenone were determined up to 24 h by a specific HPLC method. Following intravenous administration, the maximum plasma level of 2066±876 ng/ml was found after 29±15 min and thereafter the concentration declined with a half-life of 3.7±1.2 h. Total clearance was 4.2±1.7 ml/min·kg. After oral ingestion, the maximum concentration of 177±33 ng/ml was observed at 4.4±0.9 h. The absolute bioavailability of canrenone was 25±9%. Within 24 h, respectively 0.4 and 0.6 mg, canrenone were excreted by the kidney after intravenous and oral administration. The half-life of elimination was 4.9±1.8 h (i.v.) and 3.9±1.2 h (p.o.).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Karim A, Hribar J, Aksamit W, Doherty M, Chinn L (1975) Spironolactone metabolism in man studied by gas chromatography — mass spectrometry. Drug Metab Dispos 3: 467–478

    Google Scholar 

  2. Karim A, Zagarella J, Hribar J, Dooley M (1976) spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther 19: 158–169

    Google Scholar 

  3. Abshagen U, Rennekamp H, Luszpinski G (1976) Pharmacokinetics of spironolactone in man. Naunyn Schmiedeberg's Arch Pharmacol 296: 37–45

    Google Scholar 

  4. Karim A, Ranney RE, Maibach HJ (1971) Pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man. J Pharm Sci 60: 708

    Google Scholar 

  5. Sadée W, Dagcioglu M, Schöder R (1973) Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 185 (3): 686–695

    Google Scholar 

  6. Sponer G, Kaufmann G, Kuhr M (1976) Krankenhausarzt 49: 569

    Google Scholar 

  7. Abshagen U, Besenfelder E, Endele R, Koch K, Neubert B (1979) Kinetics of canrenone after single and multiple doses of spironolactone. Eur J Clin Pharmacol 16: 255

    Google Scholar 

  8. Dahlöf CG, Lundborg P, Persson BA, Regardh CG (1979) Reevaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method. Drug Metab Dispos 7 (2): 103

    Google Scholar 

  9. Huston GJ, Turner P, Leighton M (1975) Antagonism of fludrocortisone by spironolactone and canrenone. Br J Clin Pharmacol 3: 201

    Google Scholar 

  10. Ramsay L, Asbury M, Shelton J, Harrison I (1977) Spironolactone and canrenoate-K: Relative potency at steady state. Clin Pharmacol Ther 21: 602

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krause, W., Karras, J. & Seifert, W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. Eur J Clin Pharmacol 25, 449–453 (1983). https://doi.org/10.1007/BF00542109

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542109

Key words

Navigation